Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical utility of circulating tumor DNA as a response and follow-up marker in cancer therapy.

Cancer metastasis reviews - 1 Sept 2020

Boonstra Pieter A, Wind Thijs T, van Kruchten Michel, Schuuring Ed, Hospers Geke A P, van der Wekken Anthonie J, de Groot Derk-Jan, Schröder Carolien P, Fehrmann Rudolf S N, Reyners Anna K L

Abstract excerpt

Response evaluation for cancer treatment consists primarily of clinical and radiological assessments. In addition, a limited number of serum biomarkers that assess treatment response are available for a small subset of malignancies. Through recent technological innovations, new methods for measuring tumor burden and treatment response are becoming available. By utilization of highly sensitive techniques,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Circulating Tumor DNA

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Liquid Biopsy

Share to Mutation

Share to Neoplasms

Share to Predictive Value of Tests

Source

Open in PubMed Open full text

Identifiers

PMID: 32367253
DOI: 10.1007/s10555-020-09876-9
PMCID: PMC7497299

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical utility of circulating tumor DNA as a response and follow-up marker in cancer therapy.PMID 32367253Read ↗

Circulating tumor DNA to monitor treatment response in solid tumors and advance precision oncologySemantic proximity Read ↗

Molecular response assessment using circulating tumor DNA (ctDNA) in advanced solid tumors.Semantic proximity Read ↗

Toward liquid biopsies in cancer treatment: application of circulating tumor DNASemantic proximity Read ↗

Circulating tumour DNA: A new biomarker to monitor resistance in NSCLC patients treated with EGFR-TKIs.Semantic proximity Read ↗

Current Perspectives on Circulating Tumor DNA, Precision Medicine, and Personalized Clinical Management of CancerSemantic proximity Read ↗

Circulating Tumor DNA for Mutation Detection and Identification of Mechanisms of Resistance in Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Circulating Cell Free Tumor DNA Detection as a Routine Tool forLung Cancer Patient ManagementSemantic proximity Read ↗

Circulating tumor DNA in clinical trials for solid tumors: Challenges and current applicationsSemantic proximity Read ↗

Ongoing Clinical Trials and Future Research Scenarios of Circulating Tumor DNA for the Treatment of Metastatic Colorectal Cancer.Semantic proximity Read ↗

Recommendations for a practical implementation of circulating tumor DNA mutation testing in metastatic non-small-cell lung cancer.Semantic proximity Read ↗

The feasibility of using mutation detection in ctDNA to assess tumor dynamics.Semantic proximity Read ↗

Utilizing Plasma Circulating Tumor DNA Sequencing for Precision Medicine in the Management of Solid Cancers.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.